The combined study of ALX4, BMP3, NPTX2, RARB, SDC2, SEPT9, and VIM showed a sensitivity of 88.7% for stages I/II and 90.7% for all CRC stages using a model that took into account the variables of female gender and age above 66 years, with a p-value > 0.05 [40]. This evidence concerns the gene ALX4 and colorectal carcinoma.